Chemoprevention of urological cancer

Journal of Urology

Volumn 161, Issue 6, 1999, Pages 1748-1760

  Kamat, Ashish M ^a   Lamm, Donald L ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bladder neoplasms; Chemoprevention; Kidney neoplasms; Nutrition; Prostatic neoplasms

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; PYRIDOXINE; RETINOL; SELENIUM; SOYBEAN PROTEIN; ZINC;

BLADDER CANCER; CHEMOPROPHYLAXIS; DIET SUPPLEMENTATION; DIETARY INTAKE; DRUG MEGADOSE; FAT INTAKE; KIDNEY CANCER; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; REVIEW; TRANSITIONAL CELL CARCINOMA; URINARY TRACT CANCER; VITAMIN INTAKE;

EID: 0032828103     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)68793-9     Document Type: Review

References (152)

1. Devesa, S. S., Blot, W. J., Stone, B. J., Miller, B. A., Tarone, R. E. and Fraumeni, J. F., Jr.: Recent cancer trends in the United States. J. Natl. Cancer Inst., 87: 175, 1995.
2. Oliveria, S. A., Christos, P. J. and Berwick, M.: The role of epidemiology in cancer prevention. Proc. Soc. Exp. Biol. Med., 216: 142, 1997.
3. Wattenberg, L. W.: What are the critical attributes for cancer chemopreventive agents? Ann. N. Y. Acad. Sci., 768: 73, 1995.
4. Wattenberg, L. W.: Prevention-therapy-basic science and the resolution of the cancer problem. Cancer Res., 53: 5890, 1993.
5. Landis, S. H., Murray, T., Bolden, S. and Wingo, P. A.: Cancer Statistics, 1998. CA Cancer J. Clin., 48: 6, 1998.
6. Lamm, D. L. and Griffith, J. G.: Intravesical therapy: does it affect the natural history of bladder cancer? Sem. Urol., 10: 39, 1992.
7. Lutzeyer, W., Rübben, H. and Dahm, H.: Prognostic parame ters in superficial bladder cancer: an analysis of 315 cases. J. Urol., 127: 250, 1982.
8. Lotan, R.: Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochim. Biophys. Acta, 605: 33, 1980.
9. Chomienne, C., Ballerini, P., Balitrand, N., Daniel, M. T., Fenaux, P., Castaigne, S. and Degos, L.: All-trans retinoic acid in promyelocytic leukemias. II. In vitro studies: structure-function relationship. Blood, 76: 1710, 1990.
10. Fenaux, P. and Degos, L.: Differentiation therapy for acute promyelocytic leukemia. New Engl. J. Med., 337: 1076, 1997.
11. Wolbach, S. B. and Howe, P. R.: Tissue changes following deprivation of fat-soluble A vitamin. J. Exp. Med., 42: 753, 1925.
12. Tchao, R. and Leighton, J.: The effect of vitamin A on the migration and DNA synthesis of rat bladder tumor cell line NBT II in culture. Invest. Urol., 16: 476, 1979.
13. Hill, D. L. and Grubbs, C. J.: Retinoids as chemopreventive and anticancer agents intact animals (review). Anticancer Res., 2: 111, 1982.
14. Rhodes, J., Stokes, P. and Abrams, P.: Human tumour-induced inhibition of interferon action in vitro: reversal of inhibition by beta-carotene (pro-vitamin A). Cancer Immunol. Immunother., 16: 189, 1984.
15. Mettlin, C. and Graham, S.: Dietary risk factors in human bladder cancer. Amer. J. Epidemiol., 110: 255, 1979.
16. Eichholzer, M., Stähelin, H. B., Gey, K. F., Lüdin, E. and Bernasconi, F.: Prediction of male cancer mortality by plasma levels of interacting vitamins: 17-year follow-up of the prospective Basel study. Int. J. Cancer, 66: 145, 1996.
17. Hicks, R. M.: The scientific basis for regarding vitamin A and its analogues as anti-carcinogenic agents. Proc. Nutr. Soc., 42: 83, 1983.
18. Tyler, H. A., Notley, R. G., Schweitzer, F. A. and Dickerson, J. W.: Vitamin A status and bladder cancer. Eur. J. Surg. Oncol., 12: 35, 1986.
19. Flamm, J. and Grof, F.: Adjuvant local instillation with vitamin A in the therapy of bladder tumours following transurethral resection. Urologe (A), 21: 229, 1982.
20. Birt, D. F.: Update on the effects of vitamins A, C, and E and selenium on carcinogenesis. Proc. Soc. Exp. Biol. Med., 183: 311, 1986.
21. Sporn, M. B. and Newton, D. L.: Chemoprevention of cancer with retinoids. Fed. Proc., 38: 2528, 1979.
22. Moon, R. C., McCormick, D. L. and Mehta, R. G.: Inhibition of carcinogenesis by retinoids. Cancer Res., suppl., 43: 2469s, 1983.
23. Becci, P. J., Thompson, H. J., Grubbs, C. J., Brown, C. C. and Moon, R. C.: Effect of delay in administration of 13-cis-retinoic acid on the inhibition of urinary bladder carcinogenesis in the rat. Cancer Res., 39: 3141, 1979.
24. Lower, G. M., Jr. and Kanarek, M. S.: Retinoids, urinary bladder carcinogenesis, and chemoprevention: a review and synthesis. Nutr. Cancer, 3: 109, 1981.
25. Miyata, Y., Tsuda, H., Matayoshi-Miyasato, K., Fukushima, S., Murasaki, G., Ogiso, T. and Ito, N.: Effect of vitamin A acetate on urinary bladder carcinogenesis induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in rats. Gann., 69: 845, 1978.
26. Becci, P. J., Thompson, H. J., Grubbs, C. J., Squire, R. A., Brown, C. C., Sporn, M. B. and Moon, R. C.: Inhibitory effect of 13-cis-retinoic acid on urinary bladder carcinogenesis induced in C57BL/6 mice by N-butyl-N-(4-hydroxybutyl)-nitrosamine. Cancer Res., 38: 4463, 1978.
27. Mathews-Roth, M. M., Lausen, N., Drouin, G., Richter, A. and Krinsky, N. I.: Effects of carotenoid administration on bladder cancer prevention. Oncology, 48: 177, 1991.
28. Dawson, W. D., Miller, W. W. and Lues, W. B.: Retinyl acetate prophylaxis in cancer of the urinary bladder. Invest. Urol., 16: 376, 1979.
29. Pang, A. S. and Morales, A.: Chemoimmunoprophylaxis of an experimental bladder cancer with retinoids and bacillus Calmette-Guérin. J. Urol., 130: 166, 1983.
30. Moon, R. C., McCormick, D. L., Becci, P. J., Shealy, Y. F., Frickel, F., Paust, J. and Sporn, M. B.: Influence of 15 retinoic acid amides on urinary bladder carcinogenesis in the mouse. Carcinogenesis, 3: 1469, 1982.
31. Evard, J. P. and Bolag, W.: Konservative behandlung der rezidivierenden harnblasenpapillomatose mit vitamin-A-Saure. Vorlafige Mitteilung. Schweiz. Med. Wochenschr., 102: 1880, 1972.
32. Prout, G. R., Jr. and Barton, B. A.: 13-cis-retinoic acid in chemoprevention of superficial bladder cancer. The National Bladder Cancer Group. J. Cell Biochem., suppl., 161: 148, 1992.
33. Yoshida, O., Miyakawa, M., Watanabe, H., Mishina, T., Okajima, E., Hirao, Y., Matushima, M., Nihira, H. and Nakatsu, H.: Prophylactic effect of etretinate on the recurrence of superficial bladder tumors - results of a randomized control study. Hinyokika Kiyo, 32: 1349, 1986.
34. Studer, U. E., Jenzer, S., Biedermann, C., Chollet, D., Kraft, R., von Toggenburg, H. and Vonbank, F.: Adjuvant treatment with a vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumors. Final analysis of a prospective, randomized multicenter trial in Switzerland. Eur. Urol., 28: 284, 1995.
35. Alfthan, O., Tarkkanen, J., Gröhn, P., Heinonen, E., Pyrhönen, S. and Säilä, K.: Tigason (etretinate) in prevention of recurrence of superficial bladder tumors. A double-blind clinical trial. Eur. Urol., 9: 6, 1983.
36. Decensi, A., Bruno, S., Giaretti, W., Torrisi, R., Curotto, A., Gatteschi, B., Geido, E., Polizzi, A., Costantini, M. and Bruzzi, P.: Activity of 4-HPR in superficial bladder cancer using DNA flow cytometry as an intermediate endpoint. J. Cell Biochem., 161: 139, 1992.
37. Brown, R. R., Price, J. M., Satter, E. J. and Wear, J. B.: The metabolism of tryptophan in patients with bladder cancer. Acta Int. Cancer, 16: 299, 1960.
38. Talbott, M. C., Miller, L. T. and Kerkvliet, N. I.: Pyridoxine supplementation: effect on lymphocyte responses in elderly persons. Amer. J. Clin. Nutr., 46: 659, 1997.
39. Gridley, D. S., Stickney, D. R., Nutter, R. L., Slater, J. M. and Shultz, T. D.: Suppression of tumor growth and enhancement of immune status with high levels of dietary vitamin B6 in BALB/c mice. J. Natl. Cancer Inst., 78: 951, 1987.
40. Byar, D. and Blackard, C.: Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer. Urology, 10: 556, 1977.
41. Newling, D. W., Robinson, M. R., Smith, P. H., Byar, D., Lockwood, R., Stevens, I., De Pauw, M., Sylvester, R. and the EORTC Genito-Urinary Tract Cancer Cooperative Group: Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomized phase III study performed by the EORTC GU Group. Eur. Urol., 27: 110, 1995.
42. Lamm, D. L., Riggs, D. R., Traynelis, C. L. and Nseyo, U. O.: Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J. Urol., 153: 1444, 1995.
43. Benedict, W. F. and Jones, P. A.: Inhibition of transformation and oncogenic progression by ascorbic acid: a possible role in chemoprevention. In: Molecular Interrelations of Nutrition and Cancer. Edited by M. S. Arnot, J. van Eys and Y.-M. Wang. New York: Raven Press, p. 351, 1982.
44. Pohl, H. and Reidy, J. A.: Vitamin C intake influences the bleomycin-induced chromosome damage assay: implications for detection of cancer susceptibility and chromosome breakage syndromes. Mut. Res., 224: 247, 1989.
45. Nomura, A. M., Kolonel, L. N., Hankin, J. H. and Yoshizawa, C. N.: Dietary factors in cancer of the lower urinary tract. Int. J. Cancer, 48: 199, 1991.
46. Mirvish, S. S.: Effects of vitamins C and E on N-nitroso compound formation, carcinogenesis, and cancer. Cancer, suppl., 58: 1842, 1986.
47. Kakizoe, T., Takai, K., Tobisu, K., Ohtani, M. and Sato, S.: Validity of short-term examination for antipromoters of bladder carcinogenesis. Jap. J. Cancer Res., 79: 231, 1988.
48. Drake, I. M., Davies, M. J., Mapstone, N. P., Dixon, M. F., Schorah, C. J., White, K. L., Chalmers, D. M. and Axon, A. T.: Ascorbic acid may protect against human gastric cancer by scavenging mucosal oxygen radicals. Carcinogenesis, 17: 559, 1996.
49. Mirvish, S. S., Wallcave, L., Eagen, M. and Shubik, P.: Ascorbate-nitrite reaction: possible means of blocking the formation of carcinogenic N-nitroso compounds. Science, 177: 65, 1972.
50. Schlegel, J. U.: Proposed uses of ascorbic acid in the prevention of bladder carcinoma. Ann. N. Y. Acad. Sci., 258: 432, 1975.
51. Shklar, G., Schwartz, J., Trickier, D. and Cheverie, S. R.: The effectiveness of a mixture of beta-carotene, alpha-tocopherol, glutathione, and ascorbic acid for cancer prevention. Nutr. Cancer, 20: 145, 1993.
52. Mokhtar, N. M., el-Aaser, A. A., el-Bolkainy, M. N., Ibrahim, H. A., el-Din, N. B. and Moharram, N. Z.: Effect of soybean feeding on experimental carcinogenesis-III. Carcinogenecity of nitrite and dibutylamine in mice: a histopathological study. Eur. J. Cancer Clin. Oncol., 24: 403, 1988.
53. Soloway, M. S., Cohen, S. M., DeKernion, J. B. and Persky, L.: Failure of ascorbic acid to inhibit FANFT-induced bladder cancer. J. Urol., 113: 483, 1975.
54. Banic, S.: Vitamin C acts as a cocarcinogen to methylcholanthrene in guinea-pigs. Cancer Lett., 11: 239, 1981.
55. Fukushima, S., Ogiso, T., Kurata, Y., Shibata, M. A. and Kakizoe, T.: Absence of promotion potential for calcium L-ascorbate, L-ascorbic dipalmitate, L-ascorbic stearate and erythorbic acid on rat urinary bladder carcinogenesis. Cancer Lett., 35: 17, 1987.
56. Fukushima, S., Imaida, K., Sakata, T., Okamura, T., Shibata, M. and Ito, N.: Promoting effects of sodium L-ascorbate on two-stage urinary bladder carcinogenesis in rats. Cancer Res., 43: 4454, 1983.
57. Iwata, H., Yamamoto, S., Yano, Y., Ohtani, S. and Fukushima, S.: Dose-dependent amplification by L-ascorbic acid of NaHCO3 promotion of rat urinary bladder carcinogenesis. Toxicol. Path., 25: 284, 1997.
58. Kao, T. L., Meyer, W. J., III and Post, J. F.: Inhibitory effects of ascorbic acid on growth of leukemic and lymphoma cell lines. Cancer Lett., 70: 101, 1993.
59. Shibata, A., Paganini-Hill, A., Ross, R. K. and Henderson, B. E.: Intake of vegetables, fruits, beta-carotene, vitamin C and vitamin supplements and cancer incidence among the elderly: a prospective study. Brit. J. Cancer, 66: 673, 1992.
60. Byers, T., Guerrero, N.: Epidemiologic evidence for vitamin C and vitamin E in cancer prevention. Amer. J. Clin. Nutr. suppl., 62: 1385S, 1995.
61. Beisel, W. R., Edelman, R., Nauss, K. and Suskind, R. M.: Single nutrient effects on immunologic functions. Report of a workshop sponsored by the Department of Food and Nutrition and its nutrition advisory group of the American Medical Association. J.A.M.A., 245: 53, 1981.
62. Sigounas, G., Anagnostou, A. and Steiner, M.: dl-alpha-tocopherol induces apoptosis in erythroleukemia, prostate, and breast cancer cells. Nutr. Cancer, 28: 30, 1997.
63. Helzlsouer, K. J., Alberg, A. J., Norkus, E. P., Morris, J. S., Hoffman, S. C. and Comstock, G. W.: Prospective study of serum micronutrients and ovarian cancer. J. Natl. Cancer Inst., 88: 32, 1996.
64. Mirvish, S. S.: Role of N-nitroso compounds (NOC) and N-nitrosation in etiology of gastric, esophageal, nasopharyngeal and bladder cancer and contribution to cancer of known exposures to NOC. Cancer Lett., 93: 17, 1995.
65. Lamm, D. L., Riggs, D. R., Shriver, J. S., vanGilder, P. F., Rach, J. F. and DeHaven, J. I.: Megadose vitamins in bladder cancer: a double-blind clinical trial. J. Urol., 151: 21, 1994.
66. Risch, H. A., Burch, J. D., Miller, A. B., Hill, G. B., Steele, R. and Howe, G. R.: Dietary factors and the incidence of cancer of the urinary bladder. Amer. J. Epidemiol., 127: 1179, 1988.
67. Steineck, G., Hagman, U., Gerhardsson, M. and Norell, S. E.: Vitamin A supplements, fried foods, fat and urothelial cancer. A case-referent study in Stockholm in 1985-87. Int. J. Cancer, 45: 1006, 1990.
68. Lau, B. H. S., Woolley, J. L., Marsh, C. L., Barker, G. R., Koobs, D. H. and Torrey, R. R.: Superiority of intralesional immunotherapy with Corynebacterium parvum and Allium sativum in the control of murine transitional cell carcinoma. J. Urol., 136: 701, 1986.
69. Riggs, D. R., DeHaven, J. I. and Lamm, D. L.: Allium sativum (garlic) treatment for murine transitional cell carcinoma. Cancer, 79: 1987, 1997.
70. Helzlsouer, K. J., Comstock, G. W. and Morris, J. S.: Selenium, lycopene, alpha-tocopherol, beta-carotene, retinol, and subsequent bladder cancer. Cancer Res., 1;49: 6144, 1989.
71. Boone, C. W., Kelloff, G. J. and Malone, W. E.: Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: a review. Cancer Res., 50: 2, 1990.
72. Messing, E. M., Hanson, P., Reznikoff, C. A.: Normal and malignant human urothelium: in vitro response to blockade of polyamine synthesis and interconversion. Cancer Res., 48: 357, 1988.
73. Loprinzi, C. L., Messing, E. M., O'Fallon, J. R., Poon, M. A., Love, R. R., Quella, S. K., Trump, D. L., Morton, R. F. and Novotny, P.: Toxicity evaluation of difluoromethylornithine: doses for chemoprevention trials. Cancer Epidemiol. Biomark. Prev., 5: 371, 1996.
74. Rao, K. V., Detrisac, C. J., Steele, V. E., Hawk, E. T., Kelloff, G. J. and McCormick, D. L.: Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis, 17: 1435, 1996.
75. Okajima, E., Ozono, S., Endo, T., Majima, T., Tsutsumi, M., Fukuda, T., Akai, H., Denda, A., Hirao, Y., Okajima, E., Nishino, H., Nir, Z. and Konishi, Y.: Chemopreventive efficacy of piroxicam administered alone or in combination with lycopene and beta-carotene on the development of rat urinary bladder carcinoma after N-butyl-N-(4-hydroxybutyl)nitrosamine treatment. Jap. J. Cancer Res., 88: 543, 1997.
76. Moon, R. C., Kelloff, G. J., Detrisac, C. J., Steele, V. E., Thomas, C. F. and Sigman, C. C.: Chemoprevention of OH-BBN-induced bladder cancer in mice by piroxicam. Carcinogenesis, 14: 1487, 1993.
77. Moon, R. C., Kelloff, G. J., Detrisac, C. J., Steele, V. E., Thomas, C. F. and Sigman, C. C.: Chemoprevention of OH-BBN-induced bladder cancer in mice by oltipraz, alone and in combination with 4-HPR and DFMO. Anticancer Res., 14: 5, 1994.
78. Kensler, T. W., Helzlsouer, K. J.: Oltipraz: clinical opportunities for cancer chemoprevention. J. Cell Biochem., suppl., 22: 101, 1995.
79. Parker, S. L., Tong, T., Bolden, S. and Wingo, P. A.: Cancer Statistics, 1996. CA. Cancer J. Clin., 46: 5, 1996.
80. Vogelzang, N. J.: One hundred thirteen men with hormone refractory prostate cancer died today. J. Clin. Oncol., 14: 1753, 1996.
81. Wynder, E. L., Mabuchi, K. and Whitmore, W. F., Jr.: Epidemiology of cancer of the prostate. Cancer, 28: 344, 1971.
82. Shimizu, H., Ross, R. K., Bernstein, L., Yatani, R., Henderson, B. E. and Mack, T. M.: Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Brit. J. Cancer, 63: 936, 1991.
83. Fair, W. R., Fleshner, N. E. and Heston, W.: Cancer of the prostate: a nutritional disease? Urology, 50: 840, 1997.
84. Conti, C. J. and Gimenez-Conti, I. B.: Molecular genetic alterations as intermediate end points in chemoprevention studies. IARC Sci. Pub., 139: 249, 1996.
85. Rose, D. P., Boyar, A. P. and Wynder, E. L.: International comparisons of mortality rates for cancer of the breast, ovary, prostate and colon, and per capita food consumption. Cancer, 58: 2363, 1986.
86. West, D. W., Slattery, M. L., Robinson, L. M., French, T. K. and Mahoney, A. W.: Adult dietary intake and prostate cancer risk in Utah: a case-control study with special emphasis on aggressive tumors. Cancer Causes Control, 2: 85, 1991.
87. Giovannucci, E. J., Rimm, E. B., Colditz, G. A., Stampfer, M. J., Ascherio, A., Chute, C. C. and Willett, W. C.: A prospective study of dietary fat and risk of prostate cancer. J. Natl. Cancer Inst., 85: 1571, 1993.
88. Lew, E. A. and Garfinkel, L.: Variations in mortality by weight among 750,000 men and women. J. Chron. Dis., 32: 563, 1979.
89. Rose, D. P. and Connolly, J. M.: Dietary fat, fatty acids and prostate cancer. Lipids, 27: 798, 1992.
90. Godley, P. A., Campbell, M. K., Gallagher, P., Martinson, F. E., Mohler, J. L. and Sandier, R. S.: Biomarkers of essential fatty acid consumption and risk of prostatic carcinoma. Cancer Epidemiol. Biomark. Prev., 5: 889, 1996.
91. Ewings, P. and Bowie, C.: A case-control study of cancer of the prostate in Somerset and east Devon. Brit. J. Cancer, 74: 661, 1996.
92. Liang, T. and Liao, S.: Inhibition of steroid 5 alpha-reductase by specific aliphatic unsaturated fatty acids. Biochem. J., 285: 557, 1992.
93. Karmali, R. A.: Eicosanoids in neoplasia. Prev. Med., 16: 493, 1987.
94. Karmali, R. A., Reichel, P., Cohen, L. A., Terano, T., Hirai, A., Tamura, Y. and Yoshida, S.: The effects of dietary omega-3 fatty acids on the DU-145 transplantable human prostatic tumor. Anticancer Res., 17: 1173, 1987.
95. Wynder, E. L., Rose, D. P. and Cohen, L. A.: Nutrition and prostate cancer: a proposal for dietary intervention. Nutr. Cancer, 22: 1, 1994.
96. Rose, D. P.: Dietary fatty acids and prevention of hormone-responsive cancer. Proc. Soc. Exp. Biol. Med., 216: 224, 1997.
97. Clark, J. C. and Thompson, I. M.: Serum cholesterol as a risk factor for prostatic adenocarcinoma. South. Med. J., 87: 1141, 1994.
98. Thompson, I. M., Coltman, C. A., Brawley, O. W. and Ryan, A.: Chemoprevention of prostate cancer. Sem. Urol., 13: 122, 1995.
99. Hayes, R. B., Bogdanovicz, J. F., Schroeder, F. H., De Bruijn, A., Raatgever, J. W., Van der Maas, P. J., Oishi, K. and Yoshida, O.: Serum retinol and prostate cancer. Cancer, 62: 2021, 1988.
100. Hsing, A. W., McLaughlin, J. K., Schuman, L. M., Bjelke, E., Gridley, G., Wacholder, S., Chien, H. T. and Blot, W. J.: Diet, tobacco use, and fatal prostate cancer: results from the Lutheran Brotherhood Cohort Study. Cancer Res., 50: 6836, 1990.
101. Pasquali, D., Thaller, C. and Eichele, G.: Abnormal level of retinoic acid in prostate cancer tissues. J. Clin. Endocr. Metab., 81: 2186, 1996.
102. Slawin, K., Kadmon, D., Park, S. H., Scardino, P. T., Anzano, M., Sporn, M. B. and Thompson, T. C.: Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras+myc-induced carcinomas in the mouse prostate reconstitution model system. Cancer Res., 53: 4461, 1993.
103. Hsieh, T. C. and Wu, J. M.: Effects of fenretinide (4-HPR) on prostate LNCaP cell growth, apoptosis, and prostate-specific gene expression. Prostate, 33: 97, 1997.
104. Albanes, D., Heinonen, O. P., Huttunen, J. K., Taylor, P. R., Virtamo, J., Edwards, B. K., Haapakoski, J., Rautalahti, M., Hartman, A. M. and Palmgren, J.: Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. Amer. J. Clin. Nutr., suppl., 62: 1427S, 1995.
105. Fong, C. J., Sutkowski, D. M., Braun, E. J., Bauer, K. D., Sherwood, E. R., Lee, C. and Kozlowski, J. M.: Effect of retinoic acid on the proliferation and secretory activity of androgen-responsive prostatic carcinoma cells. J. Urol., 149: 1190, 1993.
106. Bouillon, R., Okamura, W. H. and Norman, A. W.: Structure function relationships in the vitamin D endocrine system. Endocr. Rev., 16: 200, 1995.
107. Schwartz, G. G. and Hulka, B. S.: Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res., 10: 1307, 1990.
108. Manchette, C. L. and Schwartz, G. G.: Geographic patterns of prostate cancer mortality: evidence for a protective effect of ultraviolet radiation. Cancer, 70: 2861, 1992.
109. Corder, E. H., Guess, H. A., Hulka, B. S., Friedman, G. D., Sadler, M., Vollmer, R. T., Lobaugh, B., Drezner, M. K., Vogelman, J. H. and Orentreich, N.: Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol. Biomark. Prev., 2: 467, 1993.
110. Braun, M. M., Helzlsouer, K. J., Hollis, B. W. and Comstock, G. W.: Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Contr., 6: 235, 1995.
111. Schwartz, G. G., Wang, M. H., Zang, M., Singh, R. K. and Siegal, G. P.: 1 alpha,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol. Biomark. Prev., 6: 727, 1997.
112. De Vos, S., Holden, S., Heber, D., Elstner, E., Binderup, L., Uskokovic, M., Rude, B., Chen, D. L., Le, J., Cho, S. K. and Koeffler, H. P.: Effects of potent vitamin D3 analogs on clonal proliferation of human prostate cancer cell lines. Prostate, 31: 77, 1997.
113. 3 receptors and actions in human prostate cancer cell lines. Endocrinology, 132: 1952, 1993.
114. Ingles, S. A., Ross, R. K., Yu, M. C., Irvine, S. A., La Pera, G., Haile, R. and Coetzee, G. A.: Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J. Natl. Cancer Inst., 89: 166, 1997.
115. Taylor, J. A., Hirvonen, A., Watson, M., Pittman, G., Mohler, J. L. and Bell, D. A.: Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res., 56: 4108, 1996.
116. Maramag, C., Menon, M., Balaji, K. C., Reddy, P. G. and Laxmanan, S.: Effect of vitamin C on prostate cancer cells in vitro: effect on cell number, viability, and DNA synthesis. Prostate, 32: 188, 1997.
117. Venugopal, M., Jamison, J. M., Gilloteaux, J., Koch, J. A., Summers, M., Hoke, J., Sowick, C. and Summers, J. L.: Synergistic antitumour activity of vitamins C and K3 against human prostate carcinoma cell. Cell Biol. Int., 20: 787, 1996.
118. Thompson, L. U.: Antioxidants and hormone-mediated health benefits of whole grains. Crit. Rev. Food Sci. Nutr., 34: 473, 1994.
119. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group: the effect of vitamin E and beta-carotene on the incidence of lung cancer and other cancers in male smokers. New Engl. J. Med., 330: 1029, 1994.
120. Willett, W. C., Polk, B. F., Morris, J. S., Stampfer, M. J., Pressel, S., Rosner, B., Taylor, J. O., Schneider, K. and Harnes, C. G.: Prediagnostic serum selenium and risk of cancer. Lancet, 2: 130, 1983.
121. Clark, L. C., Combs, G. F., Turnbull, B. W., Slater, E. H., Chalker, D. K., Chow, J., Davis, L. S., Glover, R. A., Graham, G. F., Gross, E. G., Krongrad, A., Lesher, J. L., Jr., Park, H. K., Sanders, B. B., Jr., Smith, C. L. and Taylor, J. R.: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. J.A.M.A., 276: 1957, 1997.
122. Heston, W. D., Kadmon, D., Lazan, D. W. and Fair, W. R.: Copenhagen rat prostatic tumor ornithine decarboxylase activity (ODC) and the effect of the ODC inhibitor alpha-difluoromethylornithine. Prostate, 3: 383, 1982.
123. Danzin, C., Claverie, N. and Wagner, J.: Effect on prostatic growth of 2-difluoromethylornithine, an effective inhibitor of ornithine decarboxylase. Biochem. J., 202: 175, 1982.
124. Messina, M. J., Persky, V., Setchell, K. D. and Barnes, S.: Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr. Cancer, 21: 113, 1994.
125. Fotsis, T., Pepper, M., Aldercruetz, H., Fleischmann, G., Hases, T., Montesano, R. and Schweigerer, L.: Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc. Natl. Acad. Sci., 90: 2690, 1993.
126. Khan, W. A., Wang, Z. Y., Athar, M., Bickers, D. R. and Mukhtar, H.: Inhibition of the skin tumorigenicity of (+/-)-7 beta, 8 alpha-dihydroxy-9 alpha, 10 alpha-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene by tannic acid, green tea polyphenols and quercetin in Sencar mice. Cancer Lett., 42: 7, 1988.
127. Conney, A. H., Wang, Z. Y., Huang, M. T., Lou, Y. R. and Yang, C. S.: Inhibitory effects of green and black tea on carcinogenesis. Proc. Amer. Assn. Cancer Res., 36: 704, 1995.
128. Ahmad, N., Feyes, D. K., Nieminen, A. L., Agarwal, R., Mukhtar, H.: Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J. Natl. Cancer Inst, 89: 1881, 1997.
129. Carlin, B. I., Pretlow, T. G., Pretlow, T. P. and Resnick, M. I.: Green tea polyphenols inhibit growth of prostate cancer xenograft CWR22: implications for prostate cancer chemoprevention. Proc. Amer. Assn. Cancer Res., 37: A1915, 1996.
130. Liao, S., Umekita, Y., Guo, J., Kokontis, J. M. and Hiipakka, R. A.: Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate. Cancer Lett., 96: 239, 1995.
131. Thompson, I. M., Coltman, C. A., Jr. and Crowley, J.: Chemoprevention of prostate cancer: the Prostate Cancer Prevention Trial. Prostate, 33: 217, 1997.
132. Hovenian, M. and Deming, C. L.: The heterologous growth of cancer of the human prostate. Surg. Gynec. & Obst., 86: 29, 1948.
133. Gann, P. H., Hennekens, C. H., Ma, J., Longcope, C. and Stampfer, M. J.: Prospective study of sex hormone levels and risk of prostate cancer. J. Natl. Cancer Inst., 88: 1118, 1996.
134. Imperato-McGinley, J., Gautier, T., Zirinsky, K., Horn, T., Paloma, O., Stein, E., Vaughan, E. D., Markisz, J. A., Ramirez de Arellano, E. and Kazam, E.: Prostate visualization studies in males homozygous and heterozygous for 5 alpha-reductase deficiency. J. Clin. Endocr. Metab., 75: 1022, 1992.
135. Berges, R. R., Furaya, Y., Remington, L., English, H. F., Jacks, T. and Issacs, J. T.: Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc. Natl. Acad. Sci. U.S.A., 90: 8910, 1993.
136. Marks, L. S., Partin, A. W., Gormley, G. J., Dorey, F. J., Shery, E. D., Garris, J. B., Subong, E. N., Stoner, E. and deKernion, J. B.: Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia. J. Urol., 157: 2171, 1997.
137. Brawley, O. W., Ford, L. G., Thompson, I. M., Perlman, J. A. and Kramer, B. S.: 5-alpha reductase inhibition and prostate cancer prevention. Cancer Epidemiol. Biomark. Prev., 3: 177, 1997.
138. McCredie, M.: Bladder and kidney cancers. Cancer Surv., 19-20: 343, 1994.
139. Hanash, K. A., Aquilina, J. W., Barrett, D. M., Blute, M. L., Cockett, A. T., Corica, F. A., Hillman, G. G., Zbar, B. and Zhuang, Z.: Clinical research priorities in renal cell carcinoma: renal cell carcinoma chemoprevention strategies including target populations, proposed agents, and clinical trial designs - Workgroup No. 6. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer, 80: 999, 1997.
140. Lindblad, P., Adami, H. O., Bergström, R. and Wolk, A.: Diet and risk of renal cell cancer: a population-based case-control study. Cancer Epidemiol. Biomark. Prev., 6: 215, 1997.
141. Wolk, A., Gridley, G. and Niwa, S.: International renal cell cancer study. VII. Role of diet. Int. J. Cancer, 65: 67, 1996.
142. Malvy, D. J., Burtschy, B., Arnaud, J., Sommelet, D., Leverger, G., Dostalova, L. and Drucker, J. and Amédée-Manesme, O.: Serum beta-carotene and antioxidant micronutrients in children with cancer. The "Cancer in Children and Antioxidant Micronutrients" French Study Group. Int. J. Epidemiol., 22: 761, 1993.
143. Ryuto, M., Jimi, S., Ono, M., Naito, S., Nakayama, Y., Yamada, Y., Komiyama, S. and Kuwano, M.: All-trans-retinoic acid-dependent inhibition of E-cadherin-based cell adhesion with concomitant dephosphorylation of beta-catenin in metastatic human renal carcinoma cells. J. Cancer Res., 88: 982, 1997.
144. Liehr, J. G.: Vitamin C reduces the incidence and severity of renal tumors induced by estradiol or diethylstilbestrol. Amer. J. Clin. Nutr., suppl., 54: 1256S, 1991.
145. Hirose, M., Yada, H., Hakoi, K., Takahashi, S. and Ito, N.: Modification of carcinogenesis by alpha-tocopherol, t-butylhydroquinone, propyl gallate and butylated hydroxytoluene in a rat multi-organ carcinogenesis model. Carcinogenesis, 14: 2359, 1993.
146. Zhang, D., Okada, S., Yu, Y., Zheung, P., Yamaguchi, R. and Kasai, H.: Vitamin E inhibits apoptosis, DNA modification, and cancer incidence induced by iron-mediated peroxidation in Wistar rat kidney. Cancer Res., 57: 2410, 1997.
147. Nikiforova, N. V., Chumakov, A. M., Kirpatovski, V. I. and Komarova, V. A.: Fat-soluble vitamins E and A in the tumor tissue and in the blood of patients with renal-cell cancer. Urol. Nefrol. (Moscow), 23: 1996.
148. Crespy, G.: Spontaneous recovery from metastatic cancer of the kidney. Favourable role of Vitamin E? J. Chir. (Paris), 130: 470, 1993.
149. Manolagas, S. C., Yu, X. P., Girasole, G., Bellido, T.: Vitamin D and the hematolymphopoietic tissue: a 1994 update. Sem. Nephrol., 14: 129, 1994.
150. Okamoto, T., Fujioka, T. and Horiuchi, S.: A study of the metabolism of vitamin D in patients with renal cell carcinoma -with special reference to serum concentration of 1 alpha, 25-(OH)2D and its clinical significance. Nippon Hinyokika Gakkai Zasshi, 82: 890, 1991.
151. Fujioka, T., Hasegawa, M., Ishikura, K., Matsushita, Y., Sato, M. and Tanji, S.: Inhibition of tumor growth and angiogenesis by vitamin D3 agents in murine renal carcinoma. J. Urol., 160: 247, 1998.
152. Lachance, P. A.: International perspective: basis, need, and application of recommended dietary allowances. Nutr. Rev., 56: S2, 1998.